Companies in #Ophthalmology

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is an American generics and specialty pharmaceutical company founded in 2002 by brothers Chirag and Chintu Patel, headquartered in Bridgewater, New Jersey with major manufacturing operations in India and a growing US footprint. Amneal develops, manufactures, and distributes generic and specialty pharmaceuticals across multiple dosage forms including oral solids, injectables, topicals, and ophthalmics. The company is one of the largest US-based generic drug manufacturers and has been actively reshuffling its US footprint to focus on higher-value categories including sterile injectables, biosimilars, and complex generics. Amneal was selected in June 2026 for the FDA PreCheck Pilot Program for its new Long Island, NY facility that will manufacture small molecule sterile liquid products for pain management, respiratory and ophthalmic diseases.

Bausch + Lomb is a public eye-health company focused on vision care, surgical ophthalmology, and ophthalmic pharmaceuticals.

Bayer (ETR: BAYN) is a diversified life sciences company headquartered in Leverkusen, Germany.

City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

London-based gene therapy company developing treatments for Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases, using proprietary Riboswitch gene regulation platform.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Osanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.